More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The AHA Feb. 18 responded to a request for information from Reps. Neal Dunn, R-Fla., and Lori Trahan, D-Mass., on the potential reauthorization of the Pandemic…
Headline
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
Two AHA guides offer strategies for hospitals and health systems in preparing for public health emergencies and disasters and managing cybersecurity incidents…
Headline
The National Emerging Special Pathogens Training and Education Center announced Oct. 15 that it will award $37.5 million in grants to 75 hospitals seeking to…
Headline
The Centers for Disease Control and Prevention Sept. 18 issued a health advisory on a new outbreak of Ebola in the Democratic Republic of the Congo. There are…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…